INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
February 08, 2023 08:45 ET
|
INmune Bio, Inc.
BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
Software Effective Solutions (OTC: SFWJ) Secures Distribution Agreement with Netafim, World’s Leading Drip Irrigation Technology Firm
January 12, 2023 08:30 ET
|
Software Effective Solutions Corp.
New Orleans, Louisiana, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) DBA Medcana’s Eko2o announces it has begun operations and has...
New to The Street TV Announces Five Corporate Interviews on its 413th Show Airing on the Fox Business Network, Tonight, Monday, December 5, 2022, at 10:30 PM PT
December 05, 2022 09:30 ET
|
FMW Media Works Corp
NEW YORK, Dec. 05, 2022 (GLOBE NEWSWIRE) -- FMW Media's New to The Street TV, a nationally syndicated TV show, announces episode #412th airing on the Fox Business Network tonight, Monday, December...
New to The Street / Newsmax TV Announces its Line-up for Episode #412, Nine Interviews, Airing Sunday, December 4, 2022, 10-11 AM ET
December 02, 2022 09:30 ET
|
FMW Media Works Corp
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- New to The Street / Newsmax TV announces the broadcasting line-up of its nationally syndicated 1- hour TV show this Sunday, December 4, 2022, airing time...
AB Science a reçu l’approbation de la Food and Drug Administration (FDA) américaine pour initier une étude confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
November 21, 2022 12:09 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER UNE ÉTUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA...
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease
November 21, 2022 12:09 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris,...
Software Effective Solutions’ (OTC: SFWJ) Medcana Subsidiaries Launch Construction Proceedings for Multiple Greenhouse Operations in Colombia
November 16, 2022 08:30 ET
|
Software Effective Solutions Corp.
New Orleans, Louisiana, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) DBA Medcana announces that construction operations of its five...
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
November 07, 2022 08:45 ET
|
SciSparc Ltd
Meets primary endpoints- SCI-110 administration was found to be safe at all tested dosesSCI-110 treatment was also found to reduce agitation - 75% of patients did not need to use additional medication...
Software Effective Solutions’ (OTC: SFWJ) Medcana Acquires Controlling Stake in Eko2o Environmental
November 03, 2022 10:57 ET
|
Software Effective Solutions Corp.
New Orleans, Louisiana, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) subsidiary Medcana has acquired a controlling stake in Eko2o...
Correction: Software Effective Solutions Subsidiary MEDCANA (OTC: SFWJ) Announces Successful Launch of Test Greenhouses for Microclimates and Genetics with Colombia Partner Firms
October 28, 2022 08:30 ET
|
Software Effective Solutions Corp.
New Orleans, Louisiana, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) subsidiary Medcana is pleased to announce the successful launch...